<SEC-DOCUMENT>0001564590-20-031680.txt : 20200702
<SEC-HEADER>0001564590-20-031680.hdr.sgml : 20200702
<ACCEPTANCE-DATETIME>20200702160224
ACCESSION NUMBER:		0001564590-20-031680
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200702
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200702
DATE AS OF CHANGE:		20200702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		201009195

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abio-8k_20200702.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-8k_20200702.htm
</title>
</head>
<!-- NG Converter v5.0.2.46 -->
<body>

<p style="text-align:justify;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):<font style="color:#000000;font-size:12pt;"> </font><font style="color:#000000;">July 2, 2020</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">000-22873</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Road, Suite 140, Westminster, CO</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">80020</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (720) 940-2200</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:12pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:86.67%;">
<tr>
<td style="width:25.83%;"></td>
<td style="width:20%;"></td>
<td style="width:40.83%;"></td>
</tr>
<tr style="height:12.65pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:16.6pt;">
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.001 per share</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ABIO</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC</p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:justify;margin-top:4pt;border-top:Solid 0.75pt #000000;padding-top:0pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:2pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><a name="P280769376"></a>Item 1.01</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Entry Into a Material Definitive Agreement.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2020, ARCA biopharma, Inc. (the &#8220;Company&#8221;) entered into Amendment No. 7 (the &#8220;Amendment&#8221;) to its Capital on Demand<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Sales Agreement, dated as of January 11, 2017, as amended by the Amendment No. 1, dated as of August 21, 2017, Amendment No. 2, dated as of January 25, 2019, Amendment No. 3, dated as of March 11, 2019, Amendment No. 4, dated as of May&#160;9, 2019, Amendment No. 5, dated as of May 20, 2019 and Amendment No. 6, dated as of June 28, 2019, (together, the &#8220;Sales Agreement&#8221; and, as amended by the Amendment, the &#8220;Amended Sales Agreement&#8221;), with JonesTrading Institutional Services LLC, as agent (&#8220;Agent&#8221;). The Amendment, among other things, increased the maximum aggregate offering value of shares of the Company&#8217;s common stock (the &#8220;Additional Shares&#8221;) which the Company may issue and sell from time to time under the Amended Sales Agreement (the &#8220;Offering&#8221;) by $7,636,600, from $<font style="color:#000000;">17,523,725 to $25,160,325</font>.&nbsp;&nbsp;As of July 2, 2020, the Company had sold 1,087,858 shares of its common stock<font style="color:#000000;"> </font>under the Sales Agreement for an aggregate offering price of approximately $17.4 million, before deducting sales and commissions and offering expenses. The Company will file a prospectus supplement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with the Offering (the &#8220;Prospectus Supplement&#8221;) under its existing Registration Statement on Form S-3 (File No 333-238067), which became effective on May 20, 2020 (the &#8220;Registration Statement&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="S116575981"></a>Under the Amended Sales Agreement, Agent may sell the Additional Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company may instruct Agent not to sell Additional Shares if the sales cannot be effected at or above the price designated by the Company from time to time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not obligated to make any sales of the Additional Shares under the Amended Sales Agreement. The Offering will terminate upon the earlier of (a) the sale of all of the Additional Shares subject to the Amended Sales Agreement or (b) the termination of the Amended Sales Agreement by Agent or the Company, as permitted therein.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay Agent a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Additional Shares and has agreed to provide Agent with customary indemnification and contribution rights. The Company will also reimburse Agent for certain specified expenses in connection with entering into the Amended Sales Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the Amended Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form&#160;8-K&#160;and is incorporated herein by reference. The Company previously filed the Sales Agreement as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on January 11, 2017, the Amendment No.1 as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on August&#160;21,&#160;2017, the Amendment No.2 as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on January 25, 2019, the Amendment No.3 as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on March 11, 2019, the Amendment No.4 as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on May 9, 2019, the Amendment No.5 as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on May 20, 2019 and the Amendment No.6 as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on June 28, 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP, counsel to the Company, has issued a legal opinion relating to the Additional Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Additional Shares will be sold pursuant to the Registration Statement, and offerings of the Additional Shares will be made only by means of the Prospectus Supplement and any accompanying prospectus. This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction<font style="font-size:12pt;color:#000000;">.</font> </p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 2.02 Results of Operations and Financial Condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2020, the Company provided an update on its cash balance. B<font style="Background-color:#FFFFFF;color:#000000;">ased on its cash and cash equivalents balance as of March&#160;31,&#160;2020, together with the $5.3 million of net proceeds raised in the second quarter of 2020 from sales of its common stock,</font> the Company believes its cash and cash equivalents <font style="Background-color:#FFFFFF;color:#000000;">will be sufficient to fund its operations, at its current cost structure, through the end of the second quarter of 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information provided in this Item 2.02 of this Current Report on Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements in this Current Report on Form 8-K that are not historical facts are &#8220;forward-looking statements&#8221; that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, which may be identified by use of words such as &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; and other words and terms of similar meaning, involve risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements include statements relating to any future sales under the Amended Sales Agreement or the ability of the Company&#8217;s current cash balance to fund its operations. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Actual events or results may differ materially from those stated in any such statements due to various factors, some of which are discussed in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as well as other subsequent filings by the Company with the SEC. Statements included or incorporated by reference into this Current Report on Form 8-K are based upon information known to the Company as of the date of this Current Report on Form 8-K, and the Company assumes no obligation to publicly revise or update any forward-looking statement for any reason. </p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 9 &#8212; Financial Statements and Exhibits </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:87.5%;white-space:nowrap;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex51_6.htm"><font style="text-decoration:underline;">Opinion of Cooley LLP</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex101_7.htm"><font style="text-decoration:underline;">Amendment No. 7 to Capital on Demand</font><font style="font-size:8.5pt;text-decoration:underline;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></font><font style="text-decoration:underline;">&#160;Sales Agreement, dated July 2, 2020, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex51_6.htm"><font style="text-decoration:underline;">Consent of Cooley LLP (included in Exhibit 5.1).</font></a></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:62.25%;"></td>
<td style="width:4.17%;"></td>
<td style="width:5.5%;"></td>
<td style="width:28.08%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: July 2, 2020</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Chief Accounting Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>abio-ex51_6.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex51_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.46 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 5.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gsw3m5ex10fl000001.jpg" title="" alt="" style="width:136px;height:44px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45.38%;">
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brent D. Fassett</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 720 566 4025</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bfassett@cooley.com</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:54.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 2, 2020</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.<br />11080 CirclePoint Road, Suite 140<br />Westminster, CO 80020</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M7"></a><a name="_DV_M7"></a>Ladies and Gentlemen:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M12"></a><a name="_DV_M17"></a><a name="_DV_M15"></a><a name="_DV_M16"></a>You have requested our opinion, as counsel to ARCA biopharma, Inc.<font style="color:#000000;">, a Delaware corporation (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Company</font><font style="color:#000000;">&#8221;), with respect to certain matters in connection with the offering by the Company of up to $7,636,600</font> <font style="color:#000000;">of the Company&#8217;s common stock, par value $0.001 (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Shares</font><font style="color:#000000;">&#8221;), pursuant to a<a name="_DV_M12"></a> Registration Statement on Form S-3 (No. 333-238067) (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Registration Statement</font><font style="color:#000000;"><a name="_DV_M17"></a>&#8221;)<a name="_DV_M15"></a>, filed with the Securities and Exchange Commission (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Commission</font><font style="color:#000000;">&#8221;<a name="_DV_M16"></a>) under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Act</font><font style="color:#000000;">&#8221;), the prospectus included in the Registration Statement (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Base Prospectus</font><font style="color:#000000;">&#8221;), and the prospectus supplement dated July 2, 2020, filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Prospectus</font><font style="color:#000000;">&#8221;) The Shares are to be sold by the Company in accordance with a Capital on Demand&#8482;</font><font style="font-weight:bold;color:#000000;"> </font>Sales Agreement, dated January 11, 2017 and as amended on August 21, 2017, January 25, 2019, March 11, 2019, May 9, 2019, May 20, 2019, June 28, 2019 and July 2, 2020, between the Company and JonesTrading Institutional Services LLC (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;)<font style="color:#000000;">, as described in the Prospectus.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this opinion, we have examined and relied upon the Registration Statement and the Prospectus, the Agreement, the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, and Second Amended and Restated Bylaws, as amended, and originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. In rendering this opinion, we have assumed the genuineness of all signatures; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof.&nbsp;&nbsp;As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assumed (i) that each sale of Shares will be duly authorized by the Board of Directors of the Company, a duly authorized committee thereof or a person or body pursuant to an authorization granted in accordance with Section 152 of the General Corporation Law of the State of Delaware (the &#8220;<font style="font-weight:bold;font-style:italic;">DGCL</font>&#8221;), (ii) that no more than <font style="color:#000000;">7,636,600 </font>Shares will be sold under the Agreement and (iii) that the price at which the Shares are sold will equal or exceed the par value of the Shares.&nbsp;&nbsp;We express no opinion to the extent that future issuances of securities of the Company and/or anti-dilution adjustments to outstanding securities of the Company cause the number of shares of the Company&#8217;s common stock outstanding or issuable upon conversion or exercise of outstanding securities of the Company to exceed the number of Shares then issuable under the Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our opinion herein is expressed solely with respect to the DGCL.&nbsp;&nbsp;Our opinion is based on these laws as in effect on the date hereof.&nbsp;&nbsp;We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </p>
<p style="margin-top:12pt;text-align:center;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="zzmpFIXED_LHFirstPageFooter_Text"></a><a name="zzmpFIXED_LHFirstPageFooter_Text"></a> Cooley LLP&nbsp;&nbsp; 380 Interlocken Crescent&nbsp;&nbsp; Suite 900&nbsp;&nbsp; Broomfield, CO&nbsp;&nbsp; 80021-8023<br />t: (720) 566-4000&nbsp;&nbsp;f: (720) 566-4099&nbsp;&nbsp;cooley.com</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:3.45pt;">
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gsw3m5ex10fl000001.jpg" title="" alt="" style="width:136px;height:44px;"></p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr style="height:3.45pt;">
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr style="height:26pt;">
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 2, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page Two</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:bold;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.15%;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the foregoing, and in reliance thereon, we are</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the opinion that the Shares, </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when sold and issued against payment therefor in accordance with the Agreement, the Registration Statement and the Prospectus, will be validly issued, fully paid and non</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the reference to our firm under the caption &#8220;<font style="font-weight:bold;">Legal Matters</font>&#8221; in the Prospectus and to the filing of this opinion as an exhibit to the Company&#8217;s Current Report on Form 8-K to be filed with the Commission for incorporation by reference into the Registration Statement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;">Cooley LLP</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:23.08%;">
<tr>
<td valign="top"  style="width:13.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style="width:86.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> /s/ Brent D. Fassett</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:71.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brent D. Fassett</p></td>
</tr>
</table></div>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:center;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP&nbsp;&nbsp; 380 Interlocken Crescent&nbsp;&nbsp; Suite 900&nbsp;&nbsp; Broomfield, CO&nbsp;&nbsp; 80021-8023<br />t: (720) 566-4000&nbsp;&nbsp;f: (720) 566-4099&nbsp;&nbsp;cooley.com</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>abio-ex101_7.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex101_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.46 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-bottom:5pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:5pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;"><br />AMENDMENT NO. 7 TO Capital on Demand&#8482; SALES AGREEMENT<br /></font></p>
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">July 2, 2020</font></p>
<p style="margin-bottom:5pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JonesTrading Institutional Services LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">757 Third Avenue, 23<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup> Floor</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10017</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ladies and Gentlemen:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and JonesTrading Institutional Services LLC (the &#8220;<font style="text-decoration:underline;">Agent</font>&#8221;), are parties to that certain Capital on Demand&#8482; Sales Agreement<font style="font-weight:bold;"> </font>dated January 11, 2017, as amended on August 21, 2017, January 25, 2019, March&#160;11,&#160;2019, May 9, 2019, May 20, 2019 and June 28, 2019 (together, the &#8220;<font style="text-decoration:underline;">Original</font><font style="font-weight:bold;text-decoration:underline;"> </font><font style="text-decoration:underline;">Agreement</font>&#8221;). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement.&nbsp;&nbsp;The parties, intending to be legally bound, hereby amend the Original Agreement pursuant to the terms of this amendment No. 7 to the Original Agreement (this &#8220;<font style="text-decoration:underline;">Amendment No. 7</font>&#8221;) as follows:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>The first and second paragraph of Section 1 of the Original Agreement are hereby deleted in their entirety and replaced with the following<font style="color:#0000FF;">:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>&#8220;<font style="text-decoration:underline;">Issuance and Sale of Shares</font>.&nbsp;&nbsp;The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through or to the Agent, as sales agent or principal, shares (the &#8220;<font style="text-decoration:underline;">Placement Shares</font>&#8221;) of common stock of the Company, $0.001 par value per share (the &#8220;<font style="text-decoration:underline;">Common Stock</font>&#8221;) having an aggregate offering price of up to $25,160,325, provided, however, that in no event shall the Company issue or sell through Agent such number of Placement Shares that (a) exceeds the number or dollar amount of shares of Common Stock that may be sold pursuant to the Registration Statement (as defined below), or (b) exceeds the number of authorized but unissued shares of Common Stock of the Company (the &#8220;<font style="text-decoration:underline;">Maximum Amount</font>&#8221;). Pursuant to this Agreement, shares of Common Stock were previously sold for $17,364,047 in aggregate gross proceeds under a prior prospectus and prior prospectus supplements. Under this Agreement, as amended by Amendment No. 1 to Capital on Demand&#8482; Sales Agreement, dated August 21, 2017, Amendment No. 2 to Capital on Demand&#8482; Sales Agreement, dated January 25, 2019, Amendment No. 3 to Capital on Demand&#8482; Sales Agreement, dated March 11, 2019, Amendment No. 4 to the Capital on Demand&#8482; Sales Agreement, dated May 9, 2019, Amendment No. 5 to the Capital on Demand&#8482; Sales Agreement, dated May 20, 2019, Amendment No. 6 to the Capital on Demand&#8482; Sales Agreement, dated June 28, 2019 and Amendment No. 7 to the Capital on Demand&#8482; Sales Agreement, dated July 2, 2020, the Company, through the Agent, may offer and sell further shares of Common Stock having an aggregate offering price of up to $7,636,600 pursuant to the Prospectus (as defined below).&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, the parties </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hereto agree that compliance with the limitations set forth in this Section 1 on the amount of Placement Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that Agent shall have no obligation in connection with such compliance. The issuance and sale of Placement Shares through Agent will be effected pursuant to the Registration Statement (as defined below) filed by the Company and at no earlier time than such time as the Registration Statement shall have been declared effective by the Securities and Exchange Commission (the &#8220;</font><font style="text-decoration:underline;">Commission</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue Placement Shares.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date hereof, the Company has filed Form S-3 (333-238067) (the &#8220;<font style="text-decoration:underline;">Current Registration Statement</font>&#8221;), or will file a registration statement on Form S-3, in accordance with the provisions of the Securities Act of 1933, as amended (the &#8220;<font style="text-decoration:underline;">Securities Act</font>&#8221;) and the rules and regulations thereunder (the &#8220;<font style="text-decoration:underline;">Securities Act Regulations</font>&#8221;), with the Commission, including a base prospectus, relating to certain securities, including the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="text-decoration:underline;">Exchange Act</font>&#8221;), and the rules and regulations thereunder (the &#8220;<font style="text-decoration:underline;">Exchange Act Regulations</font>&#8221;). The Company has prepared a prospectus supplement specifically relating to the Placement Shares (the &#8220;<font style="text-decoration:underline;">Prospectus Supplement</font>&#8221;) to the base prospectus included as part of such registration statement. The Company will furnish to the Agent, for use by the Agent, copies of the prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement, relating to the Placement Shares. Except where the context otherwise requires, such registration statement, and any post-effective amendment thereto, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act Regulations or deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act Regulations or any subsequent registration statement on Form S-3 filed pursuant to Rule 415(a)(6) under the Securities Act by the Company to cover any securities registered pursuant the Current Registration Statement, including any Placement Shares, as a result of the end of the three-year period described in Rule 415(a)(5) of the Securities Act, is herein called the &#8220;<font style="text-decoration:underline;">Registration Statement</font>.&#8221; The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act Regulations, together with any then issued Issuer Free Writing Prospectus (defined below), is herein called the &#8220;<font style="text-decoration:underline;">Prospectus</font>.&#8221; Any reference herein to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein.&#8221;</p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>Section 6(s) of the Original Agreement is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&#8220;Market Capitalization</font>.&nbsp;&nbsp;The aggregate market value&#160;of the outstanding voting and non-voting common equity (as defined in Securities Act Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Securities Act Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company)&#160; (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Non-Affiliate Shares</font>&#8221;), was equal to $43,385,823 (calculated by multiplying (x) the highest price at which the common equity of the Company closed on the Exchange within 60 days of the date of Amendment No. 7 to Capital on Demand&#8482; Sales Agreement times (y) the number of Non-Affiliate Shares).&nbsp;&nbsp;The Company is not a shell company (as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar months previously and if it has been a shell company at any time previously, has filed current Form 10 information (as defined in Instruction I.B.6 of Form S-3) with the Commission at least 12 calendar months previously reflecting its status as an entity that is not a shell company.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>All references to &#8220;January 11, 2017 (as amended by Amendment No. 1 to Capital on Demand&#8482; Sales Agreement, dated August 21, 2017 and as further amended by Amendment No. 2 to Capital on Demand&#8482; Sales Agreement, dated January 25, 2019, Amendment No. 3 to Capital on Demand&#8482; Sales Agreement, dated March 11, 2019, Amendment No. 4 to Capital on Demand&#8482; Sales Agreement, dated May 9, 2019, Amendment No. 5 to Capital on Demand&#8482; Sales Agreement, dated May 20, 2019 and Amendment No. 6 to Capital on Demand&#8482; Sales Agreement, dated June 28, 2019)&#8221; set forth in Schedule I and Exhibit 7(l) of the Original Agreement are revised to read &#8220;January 11, 2017 (as amended by Amendment No. 1 to Capital on Demand&#8482; Sales Agreement, dated August 21, 2017, Amendment No. 2 to Capital on Demand&#8482; Sales Agreement, dated January 25, 2019, Amendment No. 3 to Capital on Demand&#8482; Sales Agreement, dated March&#160;11, 2019, Amendment No. 4 to Capital on Demand&#8482; Sales Agreement, dated May 9, 2019, Amendment No. 5 to Capital on Demand&#8482; Sales Agreement, dated May&#160;20,&#160;2019, Amendment No. 6 to Capital on Demand&#8482; Sales Agreement, dated June&#160;28,&#160;2019 and Amendment No. 7 to Capital on Demand&#8482; Sales Agreement, dated July&#160;2,&#160;2020)&#8221;.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>Except as specifically set forth herein, all other provisions of the Original Agreement shall remain in full force and effect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font>Notwithstanding anything to the contrary contained in the Agreement, in addition to the requirements under Section 5 of the Original Agreement, the Company agrees to pay the reasonable fees and disbursements of JonesTrading&#8217;s counsel in an amount not to exceed $10,000 in connection with this Amendment No. 7 to Sales Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment No. 7 together with the Original Agreement (including all schedules and exhibits attached hereto and thereto and Placement Notices issued pursuant hereto and thereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. All references in the Original Agreement to the &#8220;Agreement&#8221; shall mean the Original Agreement as amended by this Amendment No. 7; </font><font style="font-style:italic;">provided, however</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, that </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all references to &#8220;date of this Agreement&#8221; in the Original Agreement shall continue to refer to the date of the Original Agreement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font>This Amendment shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the principles of conflicts of laws. <font style="letter-spacing:-0.15pt;">Each party hereby irrevocably submits to the non-exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any transaction contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.&nbsp;&nbsp;Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof (certified or registered mail, return receipt requested) to such party at the address in effect for notices to it under this Amendment and agrees that such service shall constitute good and sufficient service of process and notice thereof.&nbsp;&nbsp;Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font>The Company and the Agent each hereby irrevocably waives any right it may have to a trial by jury in respect of any claim based upon or arising out of this Amendment or any transaction contemplated hereby.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font>This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed amendment by one party to the other may be made by facsimile transmission.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Remainder of Page Intentionally Blank]</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the foregoing correctly sets forth the understanding among the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding amendment to the Agreement between the Company and the Agent.&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JONESTRADING INSTITUTIONAL SERVICES LLC</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;&nbsp;&nbsp;&nbsp;&nbsp; <font style="text-decoration:underline;">_/s/ Burke Cook</font>_____________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;Burke Cook</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;<font style="margin-left:36pt;">General Counsel</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ACCEPTED as of the date</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">first-above written:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">_/s/ Brian Selby</font>______________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;Brian Selby</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;Vice President, Finance</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:8pt;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">[</font><font style="font-style:italic;text-decoration:none;">Signature Page to Amendment No. 7</font><font style="text-decoration:none;">]</font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gsw3m5ex10fl000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gsw3m5ex10fl000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3! T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .7^(O_ "(FI?\ ;+_T:E>#5[S\1?\ D1-2_P"V7_HU*\&KBQ/Q
MGV_#7^Z2_P 3_)!1117.?0A7T;X:_P"15T?_ *\H?_0!7SE7T;X:_P"15T?_
M *\H?_0!73AMV?,<3?PJ?J_R-2BBBNP^."BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8^QRS/(8EJE55I_@_P#)_P!>1V'PE_Y%6Z_Z_7_] 2N\K@_A+_R*MU_U^O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOY1+>W4]S(%VAYI"Y ],GMR?SJO6+Q/9'KPX87VZGW+_ (/Z'T;_ ,)+H/\
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MOEZKNG:MJ.DR^9I][/;,65F$;D!B.FX=&'7@YZFFL3W1C5X8TO3J?>OU_P"
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M8G?8^/E&4).,E9H****"0HHHH **** "BBF2RQPQ/+*ZQQHI9W<X"@=23V%
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MW4_>*C+-R2-S'DXR<9/%7ZZXX9?:/E<3Q+5D[4(V7GJ_\E^)Y=_PI[_J._\
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M%<W,5G:374[[(84:21L$X4#).!STKYRUK59=;UFZU*8;6G?<%X.U>BKD 9P
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M%%%%!0Z**2:5(HD:21V"HB#)8GH .YKVCP7X"@T6!;W5(HY]2?#!6 9;?!R
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M;XEH<U"-7^5V^_\ X8[6BBBNT^+"O ?'>H?VCXSU%PTACA?R%60_=V#:P'/
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MTX!W)W[>PKRFBKIRY97./'85XJ@Z*ERWZVO_ )'U#17R]16_UKR/G_\ 5?\
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M%+.[G 4#J2>PKYAKDQ70^LX77\5^GZA1117*?6!1110 4444 %%%% !1110
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M444 %%%% !1110 4444 %%%% !1110 5R_Q%_P"1$U+_ +9?^C4KJ*R_$O\
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M5\5^,;WQ3.@=/L]G%S';*^X;L<LQP,GKCC@?B3E4JJ"\SU<MRJKC))[0ZO\
MR_K0]@\*>(_^$GL;N]6'R84NFAA4_>*!5.6[9))Z=.G/4[U<'\)?^15NO^OU
M_P#T!*[RJIMN*;.;,*4*.*G3@K),****LXSYPU_2VT77[W3B&"P2D)O8$E#R
MI)'&2I!_&LVO1OBUI7DZE9ZK&F%G0PRE8\#>O(+-W)!P,]D_+SFO-J1Y9-'Z
M9E^(^L8:%7JUKZ]0HHHJ#L.R^&VN_P!D^)%M)6Q;:AB%N.DG\!Z$]25[#YLG
MI7M]?+U>[>!_%D?B/2UBN)E_M2!?WZ;=N\9X<#N.F<=#V (KKP]3[+/DN(L
M[K%07D_T?Z?<=711174?*!1110 4444 %%%% !115+5M4MM%TNXU&[+""!<M
ML7)))P !ZDD#\:&[:E1C*<E&*NV<-\5M=^SV$&B0M^\N<33\=(P?E'3NPSP<
MC9[UY)5_6M5EUO6;K4IAM:=]P7@[5Z*N0!G  &<<XJA7FU)\\KGZ1EN#6$PT
M:?7=^O\ 6@4445!W!7T5X7TMM&\,Z?8.&62.(&168$J['<PR.,!B0/ZUX=X3
MT_\ M3Q7IEJ5C93.'=91E61?F8$8.<A2,5]$5U8:.\CY/B:O\%!>OZ+]0HHH
MKK/DPKYPU_2VT77[W3B&"P2D)O8$E#RI)'&2I!_&OH^O)/BUI7DZE9ZK&F%G
M0PRE8\#>O(+-W)!P,]D_+GQ$;QOV/H.'<1[/$ND]I+\5_3/.:***XC[@*[+X
M;:[_ &3XD6TE;%MJ&(6XZ2?P'H3U)7L/FR>E<;13C)Q=T88G#QQ%&5*>S_K\
M#ZAHKF?!7BF/Q+I'S[A?6RJER".&)'#C  PV"<=N1TP3TU>G&2DKH_,Z]&="
MHZ516:"BBBF9!1110 4444 %%%% !7G/Q6UW[/80:)"W[RYQ-/QTC!^4=.[#
M/!R-GO7;ZQK%EH6FR7U]+LB3@ <L[=E4=R?_ *YP 37SUJVJ7.M:I<:C=E3/
M.V6V+@  8  ]  !^%<]>I:/*NI]!D& =:M[>:]V/XO\ X&_W%*BBBN(^X"BB
MM[P9I7]L>*[&V9-T*/YTV8]Z[%YPPZ8) 7G^]WZ4TKNQG6JQI4Y5);)7/;/"
M^EMHWAG3[!PRR1Q R*S E78[F&1Q@,2!_6M>BBO32LK'Y=4J2J3<Y;MW^\**
M**9!R_Q%_P"1$U+_ +9?^C4KP:O>?B+_ ,B)J7_;+_T:E>#5Q8GXS[?AK_=)
M?XG^2"BBBN<^A"OHWPU_R*NC_P#7E#_Z *^<J^C?#7_(JZ/_ ->4/_H KIPV
M[/F.)OX5/U?Y&I11178?'!7@WQ"T[^SO&=YMB\N*YQ<)\V=VX?,>O'SA^/Z8
MKWFO-/B[I^ZTTW4E6,;':!VQ\[;AN4=.0-K]^_N:QQ$;POV/;R"O[+&*/22:
M_7]#RFBBBN ^]"O2?A)JD<5[?:7+*P:=5E@0M\N5SNP,_>((/ Z*?2O-JM:;
MJ%QI6I6]_:MMF@<.O) /J#@@X(X([@FJIRY9)G)C\-]:P\J7?;UZ'TO15+2=
M4MM:TNWU&T+&"=<KO7!!!P01Z@@C\*NUZ:=]3\TE&4).,E9H****"0HHHH *
M*** "BBB@ HJ"]O;;3K*6\O)EAMXEW.[= /ZGL!WK-T#Q1I?B.#?8SXE&=UO
M*0)5 (Y*Y/'(Y&1SZ\4KJ]C14:DH.HHOE74V:***9F%%%% !1110 4444 %%
M%% 'B'Q)T+^R?$C7<2XMM0S,O/23^,=2>I#=A\V!TKC:^@_&.A?\)#X;N+1%
MS<I^^M^?^6BYP.H'()7G@9SVKY\K@KPY9>I]_D>-^LX91E\4='^C_KL%%%%8
MGLCHI9(94EB=HY$8,CH<%2.A![&K&I:A<:KJ5Q?W3;IIW+MR2!Z 9). . .P
M JK11?H3RQYN:VH4444%!7=?"[1(]1U^74)@K1V"AE0\YD;.TX(Z##'L00M<
M+7T'X.T+_A'O#=O:.N+E_P!]<<_\M&QD=2.  O'!QGO6U"'-*_8\7/<7]7PK
M@G[TM%Z=?\OF;U%%%=Y\"%%%% !1110 4444 ,EBCFB>*5%DC=2KHXR&!Z@C
MN*\,\<>$Y/#FJ-+;PM_9<[?N'W;MAQRA/8]<9ZCN2#7NU07ME;:C92V=Y"LU
MO*NUT;H1_0]P>U9U*:FCTLMS&>"J\V\7NOZZGS+16SXE\-7OAG4C:W0WQ/DP
M3J,+*O\ 0CN.WN""<:O/::=F?H=*K"K!3@[IA1112+"MSP_XLU;PTS"QF4P.
MVYX)5W(QQC/J#TZ$9P,YQ6'133:=T9U:4*L7"HKI]SW'P[\1=)UR6.UF5K&]
MD;:D4AW(Y.<!7]>!U Y( S785\O5O:5XSU_1]BVVH2/"NT>3/^\3:O11GE1C
MCY2/T%=,,3_,?,XSAM2?-AI6\G_G_G]Y]!T5YCI?Q=C*A-6TU@P4YEM&R"<\
M#8QX&.^X]/?CHXOB/X6DB1VU%HV902CV\F5/H<*1D>Q-;JK!]3PJN58VD[.F
MWZ:_D=7161%XI\/RQ)(NM:>%=0P#W"J<'U!.0?8T_P#X270?^@WIO_@6G^-7
MS+N<GU>LOL/[F:E%9?\ PDN@_P#0;TW_ ,"T_P :R_\ A8OA7_H*_P#DO+_\
M32<XK=E1PF(G\--OY,ZBBO.[OXNZ8D0-EIMW-)NY69EC 'KD%N>G&*Y?4?BA
MXANY<VC06,89L+'&')!Z!BV<D>H ZFLY5X(]"CD6-JO6/+ZO_AW^![%J&I66
ME6C75_<QV\(_BD;&3@G '4G / Y->=^)/BHJ,]MH$:R#;_Q^2J< D'.U"!R.
M.3Z'@CFO,;FYN+R=I[J>2>9\;I)7+,<# R3STJ*L)XB3T6A[^#X>H4GS5GSO
M\/\ @_UH6M0U*]U6[:ZO[F2XF/\ %(V<#). .@&2>!P*JT45S[GT$8J*M%61
M[+\)?^15NO\ K]?_ - 2N\K@_A+_ ,BK=?\ 7Z__ * E=Y7HTO@1^<YM_OM3
MU"BBBM#SC(\3:)'X@T"YT]@HD9=T+M_!(/NG.#@=CCG!-?.\L4D,KQ2HT<B,
M5='&"I'4$=C7T_7D_P 5/#LD=ZFNVT3-%*H2Z(&0C# 5CST(P.@ VCNU<V(A
M=<R/I>'L=[.H\-/:6WK_ ,'\_4\VHHHKC/LPJ[I.J7.BZI;ZC:%1/ V5WKD$
M$8((]""1^-4J*$[:DRC&<7&2NF?0'ACQAIWBB)Q;[H;J)09+>0C('&2I_B7/
M&>.V0,BNAKYFLKVYTZ]BO+.9H;B)MR.O4'^H[$=Z](\/_%;_ %=OKMOZ+]J@
M'T&63\R2OT"UV4\0GI(^-S'(*E.3GAE>/;JO\_S/4:*I:=JVG:M%YFGWL%RH
M5681N"5!Z;AU4]>#CH:NUTIW/G91E!\LE9A11102%%,EECAB>65UCC12SNYP
M% ZDGL*Y#7?B3HNDYBM&_M&Y'\,##RQTZOR.A/W<\C!Q4RDHJ[-Z&%K8B7+2
MBVSJ[V]MM.LI;R\F6&WB7<[MT _J>P'>O"_&'C"Y\47NU=T.GQ-F& GDG^^W
MJW\N@[DYNN>(=2\17:SZC/OV9$<:C:D8)S@#\N3DG R3BLNN.K6<]%L?:95D
MT<(_:U=9_@O3_,****P/="BBNA\&^'9/$6OPPM$S643![IP. O\ =)R.6QCC
MGJ>QII-NR,ZU6%&FZDWHCT3X7^'_ .S]&?59X\7-[_J]R\K$.G49&X\]2" I
MKO*9%%'#$D42+'&BA41!@*!T '84^O2A%1C8_-,7B98FM*K+K_2"BBBJ.8*R
M/$VB1^(- N=/8*)&7="[?P2#[IS@X'8XYP36O12:35F73J2IS4X[K4^8)8I(
M97BE1HY$8JZ.,%2.H([&FUZ-\4/#'V:[36[*WQ!-Q=>6O"R9X<\_Q9QTQD<\
MM7G->;.+C*S/TO!XJ&*HQJQZ_@PHHHJ3J+^CZQ>Z%J4=]8R[)4X(/*NO=6'<
M'_ZXP0#7O/AKQ+9>)M-%U:G9*F!/ QRT3?U!['O[$$#YWJQ97MSIU[%>6<S0
MW$3;D=>H/]1V([UK2JN#\CR<SRJGC8W6DUL_T?\ 6A],T5YMX=^*EM)%';:[
M&T,JK@W<:[D<\\LH&5/3IG))Z"O0K2^M+^(RV5U!<QAMI>&0. ?3([\C\Z[8
MSC+8^(Q6!KX65JL;>?3[R>BBBK.0***BN;F"S@:>ZGC@A3&Z25PJC)P,D\=:
M!I-NR):H:QK%EH6FR7U]+LB3@ <L[=E4=R?_ *YP 37)>(/BAING^9!I2?;[
MD9'F9Q"IY'7JV"!TX(/#5Y=KGB'4O$5VL^HS[]F1'&HVI&"<X _+DY)P,DXK
M"I7C'1;GNX#(J]>2E67+'\7\O\R_XQ\5R^*=25Q'Y5G;[EMXR!NP<99CZG X
MZ#'U)YRBBN*3<G=GVM&C"A35.FK)!1112-0KV7X7^'_[/T9]5GCQ<WO^KW+R
ML0Z=1D;CSU(("FO._!OAV3Q%K\,+1,UE$P>Z<#@+_=)R.6QCCGJ>QKZ KIP\
M->9GR_$6.Y8K"PW>K].B_K]0HHHKL/CPHHHH Y?XB_\ (B:E_P!LO_1J5X-7
MO/Q%_P"1$U+_ +9?^C4KP:N+$_&?;\-?[I+_ !/\D%%%%<Y]"%?1OAK_ )%7
M1_\ KRA_] %?.5?1OAK_ )%71_\ KRA_] %=.&W9\QQ-_"I^K_(U****[#XX
M*H:UI46MZ-=:;,=JSIM#<_*W56P",X(!QGG%7Z*&KJS*A.4)*479H^8[FWEL
M[N:UG39-"[1R+D'# X(R..M15Z-\5M"^SW\&MPK^[N<0S\]) /E/7NHQP,#9
M[UYS7F3CRRL?IF"Q4<50C577?UZA1114G4=-X/\ &%SX7O=K;IM/E;,T /(/
M]]?1OY]#V(]TLKVVU&RBO+.99K>5=R.O0C^A[$=J^9:W/#?BG4?#5ZDEM(TE
MMNS+:LYV2 XSQV;@8;V[C(.]*MRZ/8\'-LFCBOWM+2?Y_P#!\SZ%HKE_#_CW
M1=>\N'S?LEXV!Y$Y W-P,*W1N3@#@G'2NHKMC)25T?%UJ%6A+DJQLPHHHIF(
M4444 %07M[;:=92WEY,L-O$NYW;H!_4]@.]<WK?Q"T+2(OW5RM_<%<I%:L&'
M?&Y^@&1@]3R#BO(M?\4:IXCGWWT^(AC;;Q$B)2 >0N3SR>3D\^G%8U*T8[:L
M]G 9+7Q+YIKECY[OT+_C3Q;<>)-2:*-]NFP.1!&N</V\QLX.2.F>@./4GG+:
MYN+.=9[6>2"9,[9(G*L,C!P1STJ*BN%R;=V?<T</3HTE2@O=1ZQX6^)\=RT=
MEKP6*5F")=HN$/'63GY3GN..>B@9KT:*6.:))8G62-U#(Z'(8'H0>XKYAKH_
M#7C35/#;A(G^T69P#;3,=JC.3L_NDY/MSR#Q713Q#6DCY_,>'XSO4PNC[=/E
MV_(]^HJ*VG^TVD,_E21>:BOY<J[73(SAAV([BI:[#XYIIV84444""BBB@ HH
MHH *\0^).A?V3XD:[B7%MJ&9EYZ2?QCJ3U(;L/FP.E>WU@^,="_X2'PW<6B+
MFY3]];\_\M%S@=0.02O/ SGM656'/$]/*,;]4Q*D_A>C_P _D?/E%%%>>?HH
M4444 %%%% '5_#W1)-7\4V\N&%O9,+B1QZ@_(N<$9+8XXX#8Z5[M7)?#G1UT
MOPI!,T6VYO?W\A."2I^X,CMMP<'H6/TKK:]"C#E@?GN=8OZSBG;:.B_7\0HH
MHK4\D**** "BBB@ HHHH **** *&L:/9:[ILEC?1;XGY!'#(W9E/8C_ZQR"1
M7B'BOP=>^%IT+O\ :+.7B.Y5-HW8Y5ADX/7'/(_$#WZF2Q1S1/%*BR1NI5T<
M9# ]01W%95*2GZGJ9=FE7!2LM8O=?Y=CYAHKT'Q;\-KC3]]]HBR75LS\VJJ6
MDB!QC'4N,Y]P,=>37GU<,H.+LS[O"XNCBH>TI.Z_+U"BBBI.D**** "BBB@
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M2LC\_J5)5)N<W=L****9 4444 <O\1?^1$U+_ME_Z-2O!J]Y^(O_ "(FI?\
M;+_T:E>#5Q8GXS[?AK_=)?XG^2"BBBN<^A"OHWPU_P BKH__ %Y0_P#H KYR
MKZ-\-?\ (JZ/_P!>4/\ Z *Z<-NSYCB;^%3]7^1J4445V'QP4444 07ME;:C
M92V=Y"LUO*NUT;H1_0]P>U> ^*?#=SX:U>2VD1OLSL6MI2<ATSQS@?,.,C^A
M!/T+6-XE\-67B;33:W0V2IDP3J,M$W]0>X[^Q (RJT^=:;GKY1F3P=6TO@>_
M^?\ 70^=Z*U-<\/:EX=NU@U&#9OR8Y%.Y) #C(/Y<'!&1D#-9=>>TT[,^^IU
M(5(J<'=,****"PK4T[Q)K6D^6+'4[F*.+.R+>6C&<Y^0Y7N3TZ\UET4)M;$3
MIPJ+EFKKS.WMOBIXA@@6.1+*X89S++$0S<]]K >W J7_ (6UKW_/IIO_ '[?
M_P"+K@Z*T]K/N<3RK!-W]FCM;OXI>([F()$;2U8-G?##DD>GSEAC\.U8.J>*
M-;UE2E_J4\L94*T0(1& .1E5P"<]R.P]*R**ESD]V;4L#AJ3O"FD_37[PHHH
MJ3J"BBB@ KT;X9^$_M<Z:_=_ZF!R+>)D^^X'W^1C )XQ_$.VWG.\#^!Y/$$J
MW]^K1Z6C<#H;@CL/1?4_@.<D>TQ11PQ)%$BQQHH5$08"@= !V%=-"E?WF?,Y
MYFRA%X:B_>>[[>7K^0^BBBNP^-"BBB@ HHHH **** "BBB@#Q#XDZ%_9/B1K
MN)<6VH9F7GI)_&.I/4ANP^; Z5QM>X_$V.V?P5<-.5\Q)8V@RV"7W8.!W.TO
MQ]3VKPZO/K149Z'Z%DF)EB,(G+>.GK;_ ( 4445D>L%;W@[0O^$A\26]HZYM
MD_?7'/\ RS7&1U!Y)"\<C.>U8->R_"_P_P#V?HSZK/'BYO?]7N7E8ATZC(W'
MGJ00%-:4H<TK'FYMB_JN%E-/WGHO5_Y;G>4445Z)^<A1110 4444 %%%% !1
M110 4444 %%%% !7*>)/ .DZ^KRQHME?,VXW$2<-R2=RY 8G)YZ].<<5U=%*
M45)69M0Q%6A/GI2LSY\UWP=K7A[+W=MOMA_R\P$O'VZGJO) ^8#)Z9K!KZAK
ME-4^'7AS4V+BU:SD+ EK1M@( QC:05 ^@'3ZURSPW\I]1A.)(VY<3'YK_+^O
M0\)HKNM4^%>MVC$V$D%_'N 4!A&^,<DAC@#/'#'M^'*:AHFJ:5N-_I]S;J'\
MO?)&0A;G@-T/0]#S7/*$H[H^@H8W#U_X4T_S^[<H4445)U!1110 4444 %%%
M;.G^$]?U3:;72KEE9/,5Y%\M&7C!#-@'KV--)O8BI5A35YM)>>AC45Z3HWPF
MN96636;Q88RH/DVQW/D@Y!8C (..F[//UKO]'\*Z+H21_8K&/SDY%Q( TI.,
M$[CR,CL,#D\<UM'#R>^AXN*S_"T=*?OORV^__*YY/X?^'6L:RS/=(VFVZ-M+
M7$3!V.,_*AQD=.21UXS@BO6M$\,Z3X?BVZ?:*LA7:\[_ #2/TSEO0X!P,#/:
MM>BNJ%*,-CY?'9KB,6[2=H]E_6H4445H>8%%%% !1110 4R6*.:)XI462-U*
MNCC(8'J".XI]% 7L>1>*?AE<V;27FAAKFW+%C:_QQ+C/RDGYQU&/O=/O<FO/
M98I(97BE1HY$8JZ.,%2.H([&OI^LC6_#.D^((MNH6BM(%VI.GRR)UQAO09)P
M<C/:N:>'3UB?2X'B*=-*&(7,N_7_ ()\ZT5WFL?"S5[6>1]+,=Y;%\1H9 DH
M7&?FSA>.G!YZX';D-1TG4=)E\O4+*>V8LRJ9$(#$==IZ,.G(SU%<LH2CNCZG
M#XW#XA?NII^77[MRE1114G4%%%% !114MM;7%Y.L%K!)/,^=L<2%F.!DX YZ
M4";25V145U>E_#KQ'J:AS:K9QE20UVVPD@XQM + _4#I]*]&\._#K2=#ECNI
MF:^O8VW)+(-J(1G!5/7D=2>0",5K"C.1Y>+SG"X=/WN9]E_GLCS;P_X"UK7O
M+F\K[)9M@^?."-R\'*KU;@Y!X!QUKV?1M"T[0+);:PMUC&T!Y"!OE(SRS=SR
M?IGC K2HKKITHPV/C\?FM?&Z2TCV7Z]PHHHK4\P**** "BBB@ HHHH ****
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MN?"\08SVV(]E':'Y]?\ (****W/!"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,:Y\)>'KJ!H9-&LE5L9,4(C;KGAEP1^!K&O/AAX;N=GD
MQ7-IMSGR)B=WUW[NGMCK7945+A%[HZJ>.Q-/X*C7S9P?_"I=!_Y^]2_[^)_\
M11_PJ70?^?O4O^_B?_$5WE%3[*'8W_M;&_\ /QG!_P#"I=!_Y^]2_P"_B?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT8X:/75_H%%%%=9\@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
